Patient with disseminated malignant tumor of the pancreas. Application of liposomal irinotecan as a new option of palliative treatment Case report

Article Sidebar

PDF


Published: Jul 12, 2021
DOI: https://doi.org/10.24292/01.OR.123120721
Keywords:
liposomal irinotecan, malignant neoplasm of the pancreas, pancreatic cancer

Main Article Content

Bogumiła Galińska
Clinical Department of Oncology, Chemotherapy and Cancer Immunotherapy, Pomeranian Medical University of Szczecin; Independent Public Clinic Hospital no. 1
Rafał Becht
Clinical Department of Oncology, Chemotherapy and Cancer Immunotherapy, Pomeranian Medical University of Szczecin; Independent Public Clinic Hospital no. 1

Abstract

In palliative treatment of pancreatic neoplasms, chemotherapy regimens with gemcitabine, nab-paclitaxel, oxaliplatin, irinotecan, 5-fluorouracil or combinations of these drugs are used. The registration of liposomal irinotecan in the treatment of stage IV disease in patients with progression after gemcitabine creates new options for the treatment choice. The described case concerns a relatively young patient in whom the use of liposomal irinotecan in the registration indication turned out to be a safe and well-tolerated treatment.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Galińska B, Becht R. Patient with disseminated malignant tumor of the pancreas. Application of liposomal irinotecan as a new option of palliative treatment. OncoReview [Internet]. 2021Jul.12 [cited 2024Nov.22];11(3(43):73-6. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/1518
Issue
Vol 11 No 3(43) (2021)
Section
PERSONALIZED ONCOLOGY
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Ducreux M, Cuhna A Sa, Caramella C et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 25(suppl 5): V56-V68.
2. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych 2019 r.
3. Wang-Gillam A, Hubner RA, Siveke JT et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019; 108: 78-87.